C&C Vision CrystaLens “Accommodating” IOL Endorsed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
C&C Vision's Model AT-45 CrystaLens likely will be the first intraocular lens (IOL) to reach the U.S. market with lens accommodation as its mechanism of action
You may also be interested in...
CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling
Eyeonics, Inc. will file a supplemental PMA for its CrystaLens AT-45 accommodating posterior chamber intraocular lens to broaden the treatment range beyond 1.0 diopter
CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling
Eyeonics, Inc. will file a supplemental PMA for its CrystaLens AT-45 accommodating posterior chamber intraocular lens to broaden the treatment range beyond 1.0 diopter
Staar’s ICL Panel Review In Sight; Three-Year Data Will Support PMA
Staar Surgical's ICL collamer phakic intraocular implant will be reviewed by FDA's Ophthalmic Devices Panel May 23